Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from CSPC Pharmaceutical Group ( (HK:1093) ).
CSPC Pharmaceutical Group has scheduled a board meeting for 27 May 2026 to consider and approve the unaudited first-quarter results for the three months ended 31 March 2026. The announcement signals the forthcoming release of early 2026 financial performance data, which will provide investors and other stakeholders with updated insight into the company’s operating trends and business momentum.
The board, chaired by Cai Dong Chen and comprising a mix of executive and independent non-executive directors, will review these preliminary numbers as part of its regular governance and disclosure obligations. This process underscores CSPC’s adherence to market transparency requirements in Hong Kong and will help shape market expectations around the company’s near-term financial health.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$13.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company listed on the Stock Exchange of Hong Kong. The group operates through multiple subsidiaries and is engaged in the development, manufacture, and sale of pharmaceutical products, serving domestic and international healthcare markets.
Average Trading Volume: 85,794,271
Technical Sentiment Signal: Buy
Current Market Cap: HK$93.29B
For an in-depth examination of 1093 stock, go to TipRanks’ Overview page.